🎉 M&A multiples are live!
Check it out!

Protagonist Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Protagonist Therapeutics and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Protagonist Therapeutics Overview

About Protagonist Therapeutics

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.


Founded

2006

HQ

United States of America
Employees

126

Financials

LTM Revenue $336M

LTM EBITDA $153M

EV

$2.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Protagonist Therapeutics Financials

Protagonist Therapeutics has a last 12-month revenue of $336M and a last 12-month EBITDA of $153M.

In the most recent fiscal year, Protagonist Therapeutics achieved revenue of $434M and an EBITDA of $256M.

Protagonist Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Protagonist Therapeutics valuation multiples based on analyst estimates

Protagonist Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $60.0M $434M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$90.3M $256M XXX XXX XXX
EBITDA Margin -151% 59% XXX XXX XXX
Net Profit -$127M -$79.0M XXX XXX XXX
Net Margin -212% -18% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Protagonist Therapeutics Stock Performance

As of April 15, 2025, Protagonist Therapeutics's stock price is $45.

Protagonist Therapeutics has current market cap of $2.8B, and EV of $2.4B.

See Protagonist Therapeutics trading valuation data

Protagonist Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.4B $2.8B XXX XXX XXX XXX $2.64

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Protagonist Therapeutics Valuation Multiples

As of April 15, 2025, Protagonist Therapeutics has market cap of $2.8B and EV of $2.4B.

Protagonist Therapeutics's trades at 7.0x LTM EV/Revenue multiple, and 15.4x LTM EBITDA.

Analysts estimate Protagonist Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Protagonist Therapeutics and 10K+ public comps

Protagonist Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.4B XXX XXX XXX
EV/Revenue 5.4x XXX XXX XXX
EV/EBITDA 9.2x XXX XXX XXX
P/E 10.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 12.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Protagonist Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Protagonist Therapeutics Valuation Multiples

Protagonist Therapeutics's NTM/LTM revenue growth is -69%

Protagonist Therapeutics's revenue per employee for the last fiscal year averaged $3.4M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Protagonist Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Protagonist Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Protagonist Therapeutics and other 10K+ public comps

Protagonist Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 624% XXX XXX XXX XXX
EBITDA Margin 59% XXX XXX XXX XXX
EBITDA Growth -383% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -10% XXX XXX XXX XXX
Revenue per Employee $3.4M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 10% XXX XXX XXX XXX
R&D Expenses to Revenue 32% XXX XXX XXX XXX
Opex to Revenue 42% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Protagonist Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Protagonist Therapeutics M&A and Investment Activity

Protagonist Therapeutics acquired  XXX companies to date.

Last acquisition by Protagonist Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Protagonist Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Protagonist Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Protagonist Therapeutics

When was Protagonist Therapeutics founded? Protagonist Therapeutics was founded in 2006.
Where is Protagonist Therapeutics headquartered? Protagonist Therapeutics is headquartered in United States of America.
How many employees does Protagonist Therapeutics have? As of today, Protagonist Therapeutics has 126 employees.
Who is the CEO of Protagonist Therapeutics? Protagonist Therapeutics's CEO is Dr. Dinesh V. Patel, PhD.
Is Protagonist Therapeutics publicy listed? Yes, Protagonist Therapeutics is a public company listed on NAS.
What is the stock symbol of Protagonist Therapeutics? Protagonist Therapeutics trades under PTGX ticker.
When did Protagonist Therapeutics go public? Protagonist Therapeutics went public in 2016.
Who are competitors of Protagonist Therapeutics? Similar companies to Protagonist Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Protagonist Therapeutics? Protagonist Therapeutics's current market cap is $2.8B
What is the current revenue of Protagonist Therapeutics? Protagonist Therapeutics's last 12-month revenue is $336M.
What is the current EBITDA of Protagonist Therapeutics? Protagonist Therapeutics's last 12-month EBITDA is $153M.
What is the current EV/Revenue multiple of Protagonist Therapeutics? Current revenue multiple of Protagonist Therapeutics is 7.0x.
What is the current EV/EBITDA multiple of Protagonist Therapeutics? Current EBITDA multiple of Protagonist Therapeutics is 15.4x.
What is the current revenue growth of Protagonist Therapeutics? Protagonist Therapeutics revenue growth between 2023 and 2024 was 624%.
Is Protagonist Therapeutics profitable? Yes, Protagonist Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.